Talphera (TLPH) Net Income towards Common Stockholders (2010 - 2026)
Talphera (TLPH) posted Net Income towards Common Stockholders of -$3.8 million for Q2 2026, up 0.71% on a QoQ basis from -$3.8 million in Q1 2026, and down 3.93% year-over-year from -$3.9 million in Q2 2025.
Analysis
Talphera (TLPH) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Talphera has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$3.8 million in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 3.93% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$14.1 million, a 11.81% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 10.97% from the prior year.
- Net Income towards Common Stockholders was -$3.8 million for Q2 2026 at Talphera, up from -$3.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $66.8 million in Q2 2022, with the low at -$13.4 million in Q1 2022.
- Average Net Income towards Common Stockholders over 5 years is $251277.8, with a median of -$3.7 million recorded in 2025.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders surged 778.14% in 2022, then tumbled 148.89% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$5.2 million in 2022, then increased by 13.07% to -$4.5 million in 2023, then jumped by 35.95% to -$2.9 million in 2024, then fell by 12.34% to -$3.2 million in 2025, then declined by 15.45% to -$3.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$3.8 million (Q2 2026), -$3.8 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | -3.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.75 Mn |
| Mar 31, 2026 | -3.78 Mn |
| Dec 31, 2025 | -3.25 Mn |
| Sep 30, 2025 | -3.34 Mn |
| Jun 30, 2025 | -3.61 Mn |
| Mar 31, 2025 | -2.77 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.83 Mn |
| Mar 31, 2024 | -4.02 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | 8.22 Mn |
| Dec 31, 2022 | -5.20 Mn |
| Sep 30, 2022 | -6.94 Mn |
| Jun 30, 2022 | 66.80 Mn |
| Mar 31, 2022 | -13.41 Mn |
| Dec 31, 2021 | -7.92 Mn |
| Sep 30, 2021 | -8.38 Mn |